GlassScriptPhysician profile
Rodney P Coe
NPI 1003972548
$15,604.67
in general payments reported to CMS, 2019-2025
21 companies · $6,599 in 2025
The $6,599 reported for 2025 was more than what 88% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,199 · 2020: $245 · 2021: $770 · 2022: $767 · 2023: $945 · 2024: $1,080 · 2025: $6,599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,068 · Food and Beverage: $3,557.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,068.00 |
| Food and Beverage | $3,556.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $5,197.12 | 2025 | Eylea Hd |
| Allergan, INC. | $4,807.90 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $1,842.57 | 2019-2025 | Eylea Hd, Eylea |
| Genentech USA, INC. | $548.13 | 2019-2025 | Vabysmo |
| Apellis Pharmaceuticals, INC. | $489.64 | 2023-2025 | Syfovre |
| Eyevance Pharmaceuticals LLC | $310.19 | 2021 | |
| Bausch & Lomb Americas INC. | $275.00 | 2024-2025 | Envista Mx60 Iol, Miebo, Xiidra |
| Sun Pharmaceutical Industries INC. | $255.77 | 2021-2025 | Cequa |
| Astellas Pharma US INC | $250.16 | 2025 | Izervay |
| Alcon Vision LLC | $227.77 | 2022-2024 | Clareon |
| Topcon Healthcare, INC. | $220.19 | 2025 | |
| Eyepoint US, INC. | $199.48 | 2021 | |
| Abbvie INC. | $198.60 | 2022-2025 | |
| Harrow Eye, LLC | $187.11 | 2025 | |
| Astellas Pharma Global Development | $127.00 | 2024-2025 | Izervay |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $123.83 | 2025 | Xdemvy |
| Recordati_rare_diseases_inc. | $122.19 | 2024 | Cystadrops |
| New World Medical,INC. | $98.09 | 2019 | |
| Carl Zeiss Meditec, INC. | $69.76 | 2019 | |
| Novartis Pharmaceuticals Corporation | $38.68 | 2019-2020 | |
| Oyster Point Pharma, INC. | $15.49 | 2025 | Tyrvaya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rodney Coe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.